Background
Sevirumab (MSL-109) is a human IgG1 neutralizing monoclonal antibody against cytomegalovirus (CMV). Sevirumab recognizes CMV gH complexes and inhibits CMV replication with an EC50 of 0.3 μg/mL.• Characterization of the human cytomegalovirus UL75 (glycoprotein H) late gene promoter., PMID:12490392• Viral shedding, and distribution of cytomegalovirus glycoprotein H (UL75), glycoprotein B (UL55), and glycoprotein N (UL73) genotypes in congenital cytomegalovirus infection., PMID:32086150• Human cytomegalovirus envelope glycoprotein B, H, and N polymorphisms among infants of Shanghai area in China., PMID:32567060• Cytomegalovirus glycoprotein H genotype distribution and the relationship with hearing loss in children., PMID:24615599• The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-kappaB during infection., PMID:9188570• Cytomegalovirus Genetic Diversity Following Primary Infection., PMID:31593588• Glycoprotein H of human cytomegalovirus (HCMV) forms a stable complex with the HCMV UL115 gene product., PMID:1328481• Distribution of the CMV glycoprotein gH/gL/gO and gH/gL/pUL128/pUL130/pUL131A complex variants and associated clinical manifestations in infants infected congenitally or postnatally., PMID:31705022• Characterization of a novel third member of the human cytomegalovirus glycoprotein H-glycoprotein L complex., PMID:9188610• Expression and reconstitution of the gH/gL/gO complex of human cytomegalovirus., PMID:12361760